Stabilizing HIF to Ameliorate Anemia

Cell. 2020 Jan 9;180(1):6. doi: 10.1016/j.cell.2019.12.010.

Abstract

Erythropoietin (EPO) production in the kidney is regulated by the oxygen-sensing transcription factor HIF-1α, which is degraded under normoxic conditions by HIF-prolyl hydroxylase (HIF-PHD). Inhibition of HIF-PHD by roxadustat leads to increased EPO production, better iron absorption, and amelioration of anemia in chronic kidney disease (CKD).

MeSH terms

  • Anemia / metabolism
  • Anemia / therapy*
  • Glycine / analogs & derivatives*
  • Glycine / therapeutic use
  • Humans
  • Hypoxia-Inducible Factor 1 / drug effects
  • Hypoxia-Inducible Factor 1 / metabolism*
  • Isoquinolines / therapeutic use*
  • Kidney / metabolism
  • Kidney / pathology
  • Prolyl Hydroxylases / drug effects
  • Prolyl Hydroxylases / metabolism
  • Renal Insufficiency, Chronic / drug therapy
  • Renal Insufficiency, Chronic / metabolism

Substances

  • Hypoxia-Inducible Factor 1
  • Isoquinolines
  • Prolyl Hydroxylases
  • Glycine
  • roxadustat